.png){kind=icon}
.png){kind=icon}
Return
Orexin receptor agonist secures landmark narcolepsy approval
.png){kind=icon}
PRE
AI
K
DOI：10.1038/d41573-026-00135-0.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists.
Journal
IF:
101.8
Papers:
5.1K
Citations:
5.3W
Organization
No organization information available
Cited Papers